The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
HIF Inhibitors: Status of Current Clinical Development
Abstract
Purpose of review In this review, the importance of the hypoxia inducible factor (HIF) pathway in tumorigenesis and cancer treatment outcomes will be discussed. The outcomes of phase II and III clinical trials of direct HIF inhibitors in the treatment of cancer will be reviewed.Recent findings The HIF signaling pathway is activated by tumor-induced hypoxia or by inactivating mutations of the VHL gene. HIF is a transcription factor which regulates the expression of genes involved in adjusting mechanisms to hypoxia such as angiogenesis or apoptosis as well as tumor growth, invasion, and metastasis. The HIF pathway has a key role in development of resistance to different treatment modalities and higher expression of the HIF molecule is associated with poor prognosis. Clinical studies of the HIF inhibitors in patients with advanced/refractory cancers suggest benefit and warrant further studies of the HIF inhibitors either as a single agent or in combination with other therapeutic agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HIF inhibitors are under pre-clinical investigation and clinical trials”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [9]
In the citing paper
“Clinical studies of HIF inhibitors indicate benefit and justify further evaluation either as a single agent or in combination with other antitumor agents (6).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [6]
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.
Semenza, G., Roth, P. H., Fang, H. M., & Wang, G. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31580-6 · Cited by 1,892
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Du, R., Lu, K. V., Petritsch, C. K., Liu, P., Ganß, R., Passegue, E. A., Song, H., VandenBerg, S. R., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,166
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154
Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5680 · Cited by 990
Hypoxia-Inducible Factor 1 (HIF-1) Pathway
Semenza, G. L. (2007) · Science s STKE · doi:10.1126/stke.4072007cm8 · Cited by 970
Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Kelly, W. K., O’Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M. L., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Secrist, J. P., Schwartz, L. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 906
Cited by
Sorted by citations
Items 301–309 of 309
Zhang, J., Qi, Y., & Sun, J. (2026) · Cryoletters · doi:10.54680/fr26210110312
Larafa, S., Schaffrin, M., Braß, P., Váraljai, R., Scharfenberg, S., Kravchenko‐Balasha, N., Polinovski, G., Herlyn, M., Tarade, N., Wiemann, S., et al. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02714-5
Bioreductive Activated Prodrugs to Target Tumor Hypoxia
Anduran, E. (2022) · theses.fr (ABES) · doi:10.70675/56ba8d97z5a2ez4c08za166z0250ebfc0763
Jiménez, C., Waguespack, S. G., Kaplan, J., Habra, M. A., & Varghese, J. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag324
Blood and lymphatic vascular remodeling in intervertebral disc degeneration
Huang, F., Lin, M., Zhang, Q., Yan, S., Li, R., Li, S., Jia, Y., Zhao, Q., Song, P., & 周海宇 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1862921
Shen, Z., Zhao, Y., Jia, M., Shi, M., Yang, Y., Sun, Y., Li, Y., Liu, X., Shan, Z., & Zhao, L. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101139
Carrero, Y. N., & Mosquera, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1922814
Smith, S. L., Rossi, S., Shukla, R., Yap, C. F., Nair, N., Butler, J., Tan, Y., Ariff, A. B. M., Lazar, I., Patel, K., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117949
BindingDB Entry 50016226: Benzo[
BindingDB (2023) · UC San Diego · doi:10.7270/q2g73jr0
Metadata
- Authors
- Fallah, J., & Rini, B. I.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Rini, Brian I.
- Venue
- Current Oncology Reports
- Published
- 2019-01
- Volume
- 21
- Issue
- 1
- Pages
- 6-6
- ISSN
- 1523-3790 (ISSN-L)
- 1534-6269
- OpenAlex
- W2913218828
- Cited by
- 308
- References
- 62
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 43 · 2023: 52 · 2022: 68 · 2021: 64 · 2020: 45 · 2019: 5
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Current Oncology Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- hypoxia-inducible factor, HIF inhibitors, tumor hypoxia, VHL mutation, angiogenesis, apoptosis, metastasis, treatment resistance, advanced cancer, clinical trials, combination therapy
- MeSH terms
- Antineoplastic Agents, Carcinoma, Renal Cell, Clinical Trials as Topic, Humans, Kidney Neoplasms, Prognosis, Research Design, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
